Big Pharma remodels with asset swaps, acquisitions

Novartis, GlaxoSmithKline Plc and Eli Lilly and Company announced a fundamental reshaping of their businesses on 22 April while yet-to-be denied rumours circulated on global stock markets of an imminent bid by Pfizer Inc for AstraZeneca Plc.